Research Paper Volume 6, Issue 8 pp 690—704

hNAG-1 increases lifespan by regulating energy metabolism and insulin/IGF-1/mTOR signaling

Xingya Wang 1, 4, , Kali Chrysovergis 1, , Justin Kosak 1, , Grace Kissling 2, , Mike Streicker 3, , Glenda Moser 3, , Ruifang Li 1, , Thomas E. Eling 1, ,

  • 1 Laboratory of Molecular Carcinogenesis,National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park NC 27709; USA
  • 2 Biostatistics Branch, National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, NC 27709; USA
  • 3 Integrated Laboratory Systems, Inc., Morrisville, NC 27560, USA
  • 4 College of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Zhejiang, China 310053

received: June 23, 2014 ; accepted: August 24, 2014 ; published: August 28, 2014 ;

https://doi.org/10.18632/aging.100687
How to Cite

Abstract

Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) or GDF15 is a divergent member of the transforming growth factor beta (TGF-β) superfamily and mice expressing hNAG-1/hGDF15 have been shown to be resistant to HFD-induced obesity and inflammation. This study investigated if hNAG-1 increases lifespan in mice and its potential mechanisms. Here we report that female hNAG-1 mice had significantly increased both mean and median life spans in two transgenic lines, with a larger difference in life spans in mice on a HFD than on low fat diet. hNAG-1 mice displayed significantly reduced body and adipose tissue weight, lowered serum IGF-1, insulin and glucose levels, improved insulin sensitivity, and increased oxygen utilization, oxidative metabolism and energy expenditure. Gene expression analysis revealed significant differences in conserved gene pathways that are important regulators of longevity, including IGF-1, p70S6K, and PI3K/Akt signaling cascades. Phosphorylation of major components of IGF-1/mTOR signaling pathway was significantly lower in hNAG-1mice. Collectively, hNAG-1 is an important regulator of mammalian longevity and may act as a survival factor. Our study suggests that hNAG-1 has potential therapeutic uses in obesity-related diseases where life span is frequently shorter.

Introduction

Aging is characterized by decline in cellular function and is associated with obesity, inflammation, altered energy metabolism, and insulin resistance [1, 2]. Understanding the mechanisms of aging with the goal of increased lifespan remains an area of intensive study. Metabolic dysfunction is a common hallmark of aging [2]. The insulin/IGF-1 (IIS) signaling pathway is the most characterized metabolic pathway implicated in aging [2, 3]. Genetic suppression of IIS signaling extends longevity in worms, insects, and mammals [1]. Caloric restriction is the only efficient treatment known to increase mammalian lifespan other than genetic modifications [4]. In early life, rodents fed a caloric restriction diet have lower IGF-1 levels than rodents fed a normal chow diet, and many rodent genetic models with a prolonged lifespan have lower levels of serum IGF-1 or IIS signaling compared to control groups [5-7]. In contrast, HFD promotes mortality and decreases lifespan in laboratory animals [8, 9].

hNAG-1 plays a complex, but poorly understood role in several human diseases [10]. Circulating hNAG-1 is elevated in physiological and pathological processes, including early pregnancy, liver injury, heart failure, and cancers [11, 12]. hNAG-1 has been shown to play a role in adiposity as transgenic mice expressing hNAG-1 have reduced body weight and fat content compared to their wild-type littermates [2, 13]. Recently, we have shown that hNAG-1 transgenic mice are resistant to both genetic and dietary-induced obesity, and have improved insulin sensitivity and higher oxidative metabolism compared to wild-type controls [14]. We also found that hNAG-1 mice have lower inflammation [15, 16]. In addition, hNAG-1 transgenic mice have significantly reduced serum level of IGF-1[14]. However, it has not been determined if hNAG-1 increases lifespan and if it alters the IGF-1/mTOR pathway, a key pathway in the regulation of aging [4].

In this study, we measured the lifespan of hNAG-1 transgenic and wild type mice and examined effects of HFD on lifespan. Lifespans of the hNAG-1 transgenic mice are significantly longer with both LFD and HFD. We also found increased oxidative metabolism, insulin sensitivity, and reduced signaling cascade of IGF-1/Insulin/mTOR in the hNAG-1 transgenic mice which may be responsible, in part, for the increased lifespan.

Results

hNAG-1 female mice have increased lifespan

A total of 200 female hNAG-1 mice and their wild-type (WT) littermates from two transgenic lines (1377 and 1398) were placed on either 10% (LFD) or 60% fat diets (HFD) (n = 25 in each line-genotype-diet group). Log-rank tests showed lifespan was significantly longer for hNAG-1 mice than for WT mice in both lines with both diets (Figure 1a and 1b, Table 1). On LFD, the median lifespan of hNAG-1 mice was 18.8 weeks (19.5%) and 13.0 weeks (12.8%) longer than WT littermates, respectively for lines 1377 and 1398 (log rank χ2 = 4.60, 1 d.f., p=0.032 for line 1377; log rank χ2 = 8.03, 1 d.f., p=0.005 for line 1398, Table 1). On HFD, the median lifespan of hNAG-1 mice was 22.4 weeks (23.6%) and 33.6 weeks (43.6%) longer than WT littermates, respectively for lines 1377 and 1398 (log rank χ2 = 13.0, 1 d.f., p<0.001 for line 1377; log rank χ2 = 28.9, 1 d.f., p<0.001 for line 1398, Table 1). Consistent with previous findings that HFD could shorten lifespan[8, 9], survival of line 1398 WT mice in the HFD group was significantly lower than the LFD group (median was 24 weeks lower, log rank χ2 = 11.2, 1 d.f., p < 0.001). However, there were no significant differences in lifespan between HFD and LFD in either WT or hNAG-1 transgenic mice in line 1377. Consistent with previous findings that young hNAG-1mice (20 to 30 weeks) are resistant to obesity on a 12 week-long HFD [14], both mean body and abdominal white adipose tissue (WAT) weights are significantly reduced in old hNAG-1 mice (> 95 weeks) after prolonged feeding with either diets (Figure 1c and 1d, Supplementary Figures 1 and 2). With aging and especially on HFD, mice (C57/BL6) develop spontaneous skin lesions and mass growths (tumors or non-tumors) in organs and experience lymph node and spleen enlargement [17-19]. Fewer hNAG-1 mice have skin lesions, spleen enlargement and gross liver lesions compared to WT littermates (Supplementary Tables 1 and 2). Percentages of mice with lymph node enlargements were similar between hNAG-1 and WT mice. Collectively, hNAG-1 overexpression increases lifespan in female mice. hNAG-1 mice are resistant to diet-induced obesity, as well as age- and diet-induced pathological lesions.

Increased lifespan of female hNAG-1 transgenic mice

Figure 1. Increased lifespan of female hNAG-1 transgenic mice. (a-b), Kaplan-Meier survival curves for female Wt and hNAG-1 mice from two transgenic lines, line 1377 and line 1398 (a) LFD (b) HFD. (c), Terminal mean body weights of hNAG-1 and Wt mice at 95±5 wk old in two lines (g). (d), Mean abdominal white adipose tissue (WAT) weights of the mice (g). n=9~18. Data are presented as mean ± SE. a, p<0.05, b, p<0.01 and c, p<0.001 as determined by Student's t-test.

Table 1. Median survival times (weeks) with comparisons of hNAG-1 and WT mice

10% Fat Diet (LFD)60% Fat Diet (HFD)
LineGenotypeNMedianP-ValueNMedianP-Value
1377NAG-125115.10.03225117.3<0.001
WT2596.32594.9
1398NAG-125114.00.00525110.6<0.001
WT25101.02577.0
Median lifespans were calculated by Kaplan–Meier survival curve analysis. Statistical comparisons between genotypes and diets was performed using the log rank test (N=25, p<0.05).

hNAG-1 female mice have increased circulating growth hormone level

In mice, disruption of growth hormone (GH) signaling that leads to major alterations in IIS has a well-documented positive impact on lifespan [4]. The long-lived GH-resistant GH receptor (GHR)-KO mice which have high GH level, as well as Ames dwarf and Snell dwarf mice lacking GHexhibit dwarfism, increased subcutaneous adiposity, change in tissue sizes, and increased insulin sensitivity[1, 20]. Although hNAG-1 mice are significantly shorter in body length (Figure 2a) there are no significant differences in tissue sizes, length of femurs or organ weights (data not shown). Interestingly, circulating GH level is substantially increased in terminal serum of hNAG-1 mice (Figure 2b). This difference is more dramatic in young 1398 female mice (Supplementary Figure 3) suggesting a possible GH-resistant phenotype or simply a feed-back regulation due to reduced IGF-1 level in hNAG-1 mice (Figure 2c). However, the expression of GHR in liver, WAT, or brain tissue at both mRNA and protein levels was the same for hNAG-1 and WT mice (data not shown). The downstream GH signaling cascade including phosphorylation of JAK2, ERK1/2, and SMAD were not different in hNAG-1 mice. Recombinant hNAG-1 did not inhibit GH-induced downstream signaling or IGF-1 secretion in cell culture studies using HepG2 cells (Data not shown). These data suggest that hNAG-1 mice are not GH resistant and the effects on longevity in hNAG-1 mice appear to be independent of GH. However, the cause of the reduction in IGF-1 levels and elevated GH levels in hNAG-1 mice is unclear.

hNAG-1 transgenic mice have improved insulin sensitivity

Figure 2. hNAG-1 transgenic mice have improved insulin sensitivity. (a), Mean body length of female hNAG-1 and Wt mice in both lines (n=6~8). (b-d), Mean serum levels of growth hormone (b), IGF-1 (c), insulin and leptin (d) in terminal blood of hNAG-1 and Wt mice on LFD and HFD (n=10). e, Insulin tolerance test on old (>95 wk) 1398 female hNAG-1 Tg mice and Wt mice (n=8~9). Data are presented as mean ±SE. a, p<0.05, b, p<0.01 and c, p<0.001 as determined by Student's t-test.

hNAG-1 female mice have increased insulin sensitivity

The resistance against HFD-induced obesity suggests that the transgenic expression of hNAG-1 in mice might positively affect age-associated metabolic disorders, such as insulin resistance. Similar to young mice [16], insulin and leptin levels are substantially reduced in hNAG-1 mice on LFD or HFD in old mice (Figure 2d).

Insulin tolerance test (ITT) shows that 95week-old (line 1398) hNAG-1 mice have significantly improved insulin sensitivity compared to WT littermates (Figure 2e). Because the body weights between hNAG-1 mice and the WT mice are quite different, it was not possible to match same weight at the same age. We decided to use the mice at the same age, which we think is more appropriate than weight. We also calculated the results using % of basal glucose level and found similar results as using glucose concentration (data not shown). Basal glucose levels are also significantly lower in 95 week-old hNAG-1 transgenic mice. Thus, consistent with association between improved insulin sensitivity with better survival [4], older hNAG-1 mice sustain higher insulin sensitivity which may play a role, in part, for the increased lifespan as observed above. hNAG-1 mice mimic caloric restriction with reduced circulating IGF-1 levels, improved insulin sensitivity, and extended lifespan. There is no significant difference in food intake between the mice on a LFD or HFD in both lines (Supplementary Figure 4 and 5).

hNAG-1 have increased energy expenditure and metabolism

Increased energy expenditure can extend lifespan and alter insulin sensitivity and resistance to obesity [21, 22]. Previously, we have shown that hNAG-1 expression increases metabolic oxidation and thermogenesis in male mice which is responsible, in part, for the resistance of hNAG-1 mice to obesity [14]. Enhanced O2 consumption and higher heat expenditure are consistent with increased oxidative metabolism and is associated with protection from HFD-induced obesity and enhanced longevity [1, 23]. In this study, heat production is slightly but statistically significant lower during the day in female line 1398 hNAG-1 mice (Figure 3a). During the night, hNAG-1 mice have significantly much higher heat production than WT littermates (Figure 3a) with no difference in physical activity between the mice (data not shown). We then examined the expression of representative thermo-genesis genes in brown adipose tissue (BAT) in both 30 wk and 95 wk old mice. However, unlike the young male mice where most of these genes (UCP-1, PGC1a, ECH-1, Cox8b, PGC1b, etc) are up regulated in BAT [14], only few genes were up regulated in BAT in female mice due to larger variation (Supplementary Figure 6). In addition, hNAG-1 mice utilize more oxygen than WT mice during the night (Figure 3b) and have reduced respiratory quotient (RQ) during the day (Figure 3d), implying greater reliance on fats, as opposed to carbohydrates, as an energy source.

hNAG-1 transgenic mice have increased metabolism

Figure 3. hNAG-1 transgenic mice have increased metabolism. (a), Heat production (W/kg) in female hNAG-1 and Wt mice as determined indirect colorimeter (n=5). (b-c), Consumption of O2 and VO2 (ml/h/kg) in female hNAG-1 and Wt mice during day and night time (n=5). (d), Respiratory quotient (RER) as calculated from VO2 and VCO2 in 1398 hNAG-1 female mice. Data are presented as mean ± SE. a, p<0.05, b, p<0.01 and c, p<0.001 as determined by Student's t-test.

hNAG-1 female mice have decreased mTOR signaling activity

To further understand the mechanism of extended lifespan in hNAG-1 mice, we used whole genome microarray analysis to examine differential gene expression in abdominal WAT in line 1398 hNAG-1 mice. Differential category expression analysis showed significant differences between hNAG-1 mice and WT mice in key pathways in the regulation of metabolism and mammalian lifespan, including down regulation of IGF-1, PI3K, AMPK, and RPS6K families (Supplementary Fig. 7, Table 2). We validated a set of genes (mTorc2, GHRH, IGF1R, RPS6k, FOXO1, Raptor, Mlst8, Mapkap1, Pik3c9) by qRT-PCR in young female mice (Figure 4a). The expression pattern of all of these genes confirmed the microarray data with a similar expression pattern in old mice (> 95 wk) except for FOXO1 (Figure 4b).

Table 2. Ingenuity canonical pathways enriched by genes differentially expressed in hNAG-1 mice

Ingenuity Canonical PathwaysMolecules
Significantly changed
 PTEN SignalingRPS6KB1,FOXO1,MAPK1,BMPR1A,FGFR1,IGF1R,MRAS,ITGA5,KRAS,EGFR
 IGF-1 Signaling RPS6KB1,NEDD4,FOXO1,MAPK1,IGF1R,SRF,MRAS,KRAS
p70S6K Signaling GNAI2,RPS6KB1,F2RL1,MAPK1,MRAS,PRKCE,KRAS,PPP2R5A,EGFR
ErbB Signaling RPS6KB1,FOXO1,MAPK1,MRAS,PRKCE,KRAS,EGFR
AMPK Signaling RPS6KB1,CHRNA4,ACACB,MAPK1,MRAS,ACACA,CHRNE,AK2,PPP2R5A
Growth Hormone Signaling RPS6KB1,MAPK1,IGF1R,SRF,RPS6KA3,PRKCE
PI3K/AKT Signaling RPS6KB1,FOXO1,MAPK1,MRAS,ITGA5,KRAS,PPP2R5A,THEM4
ERK/MAPK Signaling BRAF,MAPK1,PLA2G4C,SRF,MRAS,PRKCE,ITGA5,TLN1,KRAS,PPP2R5A
Non-Significantly changed
HIF1α Signaling SLC2A5,MAPK1,Vegfb,MRAS,EGLN3,KRAS
EGF Signaling RPS6KB1,MAPK1,SRF,EGFR
ErbB2-ErbB3 Signaling FOXO1,MAPK1,MRAS,KRAS
mTOR Signaling RPS6KB1,RND3,MAPK1,Vegfb,MRAS,RPS6KA3,PRKCE,KRAS,PPP2R5A
ErbB4 Signaling MAPK1,MRAS,PRKCE,KRAS
Role of JAK1 and JAK3 in γc Cytokine Signaling MAPK1,SH2B2,MRAS,KRAS
Regulation of eIF4 and p70S6K Signaling RPS6KB1,MAPK1,AGO3,MRAS,ITGA5,KRAS,PPP2R5A
Insulin Receptor Signaling RPS6KB1,FOXO1,MAPK1,SH2B2,MRAS,KRAS
JAK/Stat Signaling MAPK1,MRAS,KRAS
PI3K Signaling in B Lymphocytes MAPK1,SH2B2,MRAS,KRAS
IPA analysis was used to generate a list of genes changed in canonical pathway. Significance was calculated
Gene validation from microarray results

Figure 4. Gene validation from microarray results. Validation was analyzed by qRT-PCR. (a-b), Validation of the expression of down-regulated genes from microarray study in young (30 wk, a) and old (95 wk, b) abdominal white adipose tissue (WAT) of female mice (n=6). Data are presented as mean ± SE. a, p<0.05, b, p<0.01 and c, p<0.001 as determined by Student's t-test.

mTOR pathway is emerging as a key regulator of aging, and is linked to IIS pathway [7, 24]. Inhibition of mTOR activity or knockout the downstream effector of mTOR, S6K1, increases lifespan in mice [25, 26].

Phosphorylation of members of mTOR signaling pathway (IGF1R, mTOR (ser2448), AKT (ser308), p70S6k (ser 384), and 4EPB-1) is down regulated in the WAT of young 1398 hNAG-1 mice (Fig. 3f), and similar pattern is observed in old mice (> 95 wk, Figure 5). The expression of Sirt1 and Sirt6 [6, 27] between hNAG-1 and WT mice was not different in liver (data not shown) and abdominal WAT (Figure 5).

hNAG-1 transgenic mice have reduced IGF-1/Insulin/mTOR signaling

Figure 5. hNAG-1 transgenic mice have reduced IGF-1/Insulin/mTOR signaling. Phosphorylation of proteins of IGF-1/insulin/mTOR signaling pathway was analyzed by Western blot (n=3) in abdominal WAT. Both samples from 30 wk and 95 wk old animals were analyzed.

Discussion

Aging is characterized by decline in cellular function and is associated with obesity, inflammation, energy metabolism, and insulin resistance [1, 2]. In this study, we report that hNAG-1 is a novel regulator of mammalian longevity. Both the median and mean lifespan of the female hNAG-1 mice on HFD and LFD are significantly longer than the WT mice. In the male hNAG-1 transgenic mice, elevated circulating serum levels of hNAG-1 increases thermogenesis and oxidative metabolism [14], inhibits inflammation [15] and improves glucose tolerance [14]. In this study, we also found that female hNAG-1 mice have increased metabolism and insulin sensitivity.

Furthermore, differential gene expression analysis revealed significant differences in the expression of key pathways associated with metabolism and mammalian lifespan between the hNAG-1 mice and wild-type littermates. Our study suggests that hNAG-1 improves mammalian survival by increasing energy metabolism and reducing IGF-1/mTOR signaling, two well-studied and tightly regulated longevity networks [4]. These biochemical events are conserved across species and are associated with increased longevity in all organisms and thus it can be assumed they have a role in the increased lifespan in female hNAG-1 mice as summarized in Figure 6. The hNAG-1 mice have most of the metabolic characteristic of long-lived mice [1]. In addition, we have previously reported that the hNAG-1 mice have a lower inflammatory response [15, 16], and inflammation has been associated with aging [28, 29]. In contrast to most long-lived animals in which genetic deletion increases life span, we shown here that an increase in the expression of hNAG-1 protein extended longevity. hNAG-1 has similar effects as observed in Klotho transgenic mice in which lifespan has also been extended by perturbing IGF-1 signaling [30]. hNAG-1 is a circulating protein and thus there are opportunities and ways to alter metabolic activity and influence longevity by increase the circulating levels of hNAG-1 in humans. This is the first report showing hNAG-1 can act to increase lifespan in mice.

Schematic model for increased survival and lifespan in hNAG-1 mice

Figure 6. Schematic model for increased survival and lifespan in hNAG-1 mice. Overexpression of hNAG-1 in female mice lowers serum levels of IGF-1 and insulin and thus reduces IGF-1/insulin (IIS)/mTOR signaling. Circulating hNAG-1 also increases lipolysis, thermogenesis, and metabolism in hNAG-1 mice [14], and reduces macrophage infiltration into WAT and reduces inflammation in hNAG-1 mice [15, 16]. hNAG-1 mice are thus resistant to obesity, have increased energy metabolism and increased insulin sensitivity, which leads to increased lifespan, and reduced age- or dietary-induced pathological lesions.

In laboratory mice, mutations with GH or GHR have been well documented to have positive impact on lifespan [1]. These mutations lead to alterations in IIS cascade and downstream signaling pathways. In this study, we found that GH is substantially up-regulated in hNAG-1 mice. Notably, GHR deficient mice also have significantly increased GH level which causes GH resistance [20]. As expected, circulating IGF-1 levels are significantly reduced in old female mice. In line with our findings, IGF-1 deficient mice also produce elevated levels of GH [31], suggesting a possible similarity of growth hormone resistance between hNAG-1 mice and GHR deficient mice. However, we did not detect any differences of GHR expression at mRNA and protein levels between hNAG-1 and WT mice in liver, brain, and adipose tissues. In addition, in vitro cell culture studies also failed to prove hNAG-1 may have inhibitory effects on GH downstream signaling or IGF-1 secretion from cells upon GH treatment. Interestingly, a striking difference between GHR deficient or GH disrupted mice and hNAG-1 mice is that GHR deficient mice are rather obese which have increased subcutaneous adiposity while hNAG-1 mice have decreased adiposity [1]. These data suggest that the mechanisms how IGF-1 level is significantly reduced and why GH levels is elevated in hNAG-1 mice is still unclear. hNAG-1 mice may have both an overlapping and different mechanisms with GH deficient and resistant animals that have a significant effect on extending lifespan.

Female IGF1R heterozygous knockout mice live on average 33% longer than their wild-type littermates, suggesting IGF-1 receptor may be a central regulator of mammalian lifespan [5]. In line with this observation, the expression of IGFR at mRNA level is significantly reduced in adipose tissue of hNAG-1 mice then WT mice. In addition, the phosphorylation of IGF1R is also significantly reduced in hNAG-1 mice compared to wild-type littermates. The nutrient sensing mTOR pathway is emerging as a key regulator of ageing. mTOR signaling complex affecting several crucial cellular functions, which show clear effects on ageing [24]. mTOR activity is linked to IIS pathway through multiple connections. Inhibition of mTOR by rapamycin or knockout the downstream effector of mTOR, the S6K1 (Rps6k), were reported to increase lifespan in mice [26]. Both microarray data and validation studies suggest that the key family of mTOR pathway and its downstream signaling are downregulated in hNAG-1 mice. These findings are consistent with studies showing reduced phosphorylation of insulin/IGF-1/mTOR signaling pathway in WAT which is positively linked with prolonged lifespan [24].

The expression of hNAG-1 is significantly higher in many physical conditions and diseases in humans [11, 32]. The serum level of hNAG-1 is higher in patients with cancer, after cardiovascular incidence for example a heart attack, and liver or lung injuries, but is also higher during pregnancy [11, 32]. Serum levels of hNAG-1 have been proposed as a marker for all-cause mortality with concentrations correlated with survival time [33]. These apparent contradictory findings may point to pleiotropic/diverse functions of hNAG-1 in many diseases and physiological conditions. However, a rational explanation for these observations is that hNAG-1 expression is increased by the cellular injury and is acting as a survival factor. Thus, an increase in circulating levels of mature hNAG-1 observed, with the level assumed to be directly related to the severity of the disease/injury. hNAG-1 mice are protected against chemical and genetically induced intestinal cancers and have lower inflammatory response [15, 34], while the circulating level of hNAG-1 is higher in cancer patients. Likewise, other evidences from mice experiments indicate that hNAG-1 protects the heart from ischemia/reperfusion [31] and hypertrophic injury [12] while circulating levels of hNAG-1 are increased after a cardiovascular event. In cancer patients the increased circulating hNAG-1 is related to the weight loss/cachexia observed [28, 29]. These seemingly conflicting results are consistent with the hypothesis that hNAG-1 acts as a survival factor.

Our recent studies confirmed that raising the circulating levels of the secreted mature hNAG-1 increases thermogenesis and oxidative metabolism causing a dramatic reduction in body and fat contents [14]. hNAG-1 exists in many forms, the pro-monomer, the pro-dimeric form and the secreted dimeric protein is present in the circulation, but the biological activity of the different hNAG-1forms is poorly understood [30]. The conflicting and contradictory findings may be related to some differences in the biological activities of the forms of hNAG-1. In addition, the receptor(s) of hNAG-1 has not been characterized and thus some difference in findings could be related to differences or mutation in these uncharacterized receptors.

In summary, hNAG-1 increased longevity and lifespan in female transgenic mice expressing the human hNAG-1 protein. hNAG-1 increases oxidative metabolism, lower obesity and decrease the insulin/IGF-1 pathway, all of which are associated with survival and longevity. These findings suggest hNAG-1 is a possible novel protein with potential therapeutic uses in diseases such as diabetes and obesity where shorter life span frequently is observed.

Methods

Animals

The hNAG-1 transgenic mice were generated as described previously [34]. hNAG-1 is expressed in most tissues, liver is very low but good expression is found in the skin, colon, kidney, brain and is highly expressed in the WAT and BAT (data not shown). Experiments were performed in accordance with the “NIH Guidelines for the Use and Care of Laboratory Animals”. A total of 200 WT and hNAG-1 female transgenic mice at 50 wk old from line 1377 and 1398 were randomized and fed LFD or HFD (Research Diet) and water ad libitum (n=25/group). A total of 200 male mice were initially included for longevity study. However, due to relative high percentage of male hNAG-1 mice that develop, for unknown reasons, urinary blockage which can cause early death the male mice were removed from study. Food intake was measured once a week for 40 weeks. Body weights were measured twice weekly over the course of the study. The mice were euthanized and total fat was removed and weighed. Physical activity, VO2, VCO2, and body heat production were measured at 30 wk of age in line 1398 female mice as described previously [35].

Insulin Tolerance Test

Female mice, 95 wk old (1398), were fasted for 6 h and insulin (Sigma, St. Louis, MO) was intraperitoneally injected into mice at dose of 0.5 U/kg BW. Blood was collected from the tail at 0, 15, 30, 60, and 90 min after injection and glucose concentration was analyzed using a glucose meter.

Microarray Analysis

RNA samples from abdominal WAT of line 1398 female NAG-1 mice and WT mice at 30 wk old were extracted as described [16]. Sample hybridization was performed as previously described [36]. Microarray analysis was performed using Affymetrix Mouse Genome 430 2.0 Array by Microarray core at NIEHS. Pathway analysis was carried out using Ingenuity Pathway Analysis (IPA, http://www.Ingenuity.com). Separate statistical analyses were conducted for each transgenic line.

Real-time PCR

RNA samples from abdominal WAT and BAT of line 1398 female NAG-1 mice and WT mice at 30 wk old were extracted as described[16]. One microgram of RNA was reverse transcribed using iScript cDNA synthesis kit from BioRad. Real-time PCR assays were performed using Taqman master mix and primers (Applied Biosystems, Foster City, CA) by MyiQ PCR detection system (BioRad) for semi-quatitative real-time PCR analysis. Relative fold changes were calculated using the delta delta Ct method, with β-actin or GAPDH serving as control genes.

ELISA Analysis

Terminal bleeds from mice were incubated at room temperature for 1 hour in serum separator tubes (Sarstedt, Nümbrecht, Germany) and then spun at 10,000 × rpm for 5 minutes. Serum was collected and stored at −80°C until analysis. Mouse leptin, mouse growth hormone, human NAG-1, mouse IGF-1 (R&D, Minneapolis, MN) and mouse insulin (Alpco, Salem, NH) ELISA kits were used according to manufacturer's instructions.

Western Blots

Western Blots were performed as described[16]. Total protein in abdominal WAT was isolated using RIPA buffer (Pierce, Rockford, IL) supplemented with sodium fluoride and sodium vanadate. A total of 45 μg protein was electrophoresed on a 4-15% SDS-polyacrylamide Tris-Hcl gel (Bio-Rad) at 175V for 1 h. After transfer, membranes were blocked with 5% non-fat dry milk in 1x TBST (50Mm Tris pH7.5, 150 mM NaCl, 0.1% Tween-20) at room temperature for 1 hour. The membrane was probed overnight at 4°C with appropriate antibodies, at the dilutions as recommended by their manufactures. The next day, blots were rinsed and probed with the appropriate horseradish-peroxidase secondary antibody for 1 hour at room temperature in 5% milk in TBST and illuminated with Western Lightening TM Plus-ECL Enhanced Chemiluminescence Substrate assay kit. The membrane was stripped using Restore Western Blot Stripping Buffer according to manufacturer's instruction. After stripping, the membrane was re-probed for GAPDH for loading control.

Statistical Analysis

Data were analyzed by Dr. Grace Kissling of the NIEHS Biostatistics Branch who determined the appropriate method to use. Survival was compared between genotypes and diets using log-rank tests; survival curves were plotted from Kaplan-Meier estimates. Body weight was compared between genotypes and diets using polynomial growth curve analysis. Food consumption was compared between genotypes and diets using Mann-Whitney tests with Bonferroni correction for multiple testing. All p-values are two-sided and considered significant at the 0.05 level. Body weight and food consumption plots show mean ± standard error of the mean.

Supplementary Materials

Supplemental File

Acknowledgements

We thank Drs. Xiaoling Li and Paul Wade for critical reading of this manuscript. We wish to thank Laura Wharey, Kevin Gerrish, and Ruchir Shah at NIEHS Microarray core for performing microarray experiment and data analysis. This research was supported by NIH, NIEHS Intramural Research Program (Eling) Z01- ES010016-14.

Conflicts of Interest

Conflict of interest statement

There is no conflicting interest by all authors.

References

  • 1. Bartke A and Westbrook R. Metabolic characteristics of long-lived mice. Front Genet. 2012; 3-288. [PubMed]
  • 2. Houtkooper RH, Argmann C, Houten SM, Canto C, Jeninga EH, Andreux PA, Thomas C, Doenlen R, Schoonjans K, Auwerx J. The metabolic footprint of aging in mice. Sci Rep. 2011; 1-134. [PubMed]
  • 3. Russell SJ and Kahn CR. Endocrine regulation of ageing. Nat Rev Mol Cell Biol. 2007; 8:681-691. [PubMed]
  • 4. Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol. 2013; 9:366-376. [PubMed]
  • 5. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, Cervera P, Le Bouc Y. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature. 2003; 421:182-187. [PubMed]
  • 6. Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L, Bar-Joseph Z, Cohen HY. The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012; 483:218-221. [PubMed]
  • 7. Kenyon CJ. The genetics of ageing. Nature. 2010; 464:504-512. [PubMed]
  • 8. List EO, Berryman DE, Wright-Piekarski J, Jara A, Funk K, Kopchick JJ. The effects of weight cycling on lifespan in male C57BL/6J mice. Int J Obes (Lond). 2013; 37:1088-1094. [PubMed]
  • 9. Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, Yamaguchi M, Tanabe H, Kimura-Someya T, Shirouzu M, Ogata H, Tokuyama K, Ueki K, et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013; 503:493-499. [PubMed]
  • 10. Eling TE, Baek SJ, Shim M, Lee CH. NSAID activated gene (NAG-1), a modulator of tumorigenesis. Journal of biochemistry and molecular biology. 2006; 39:649-655. [PubMed]
  • 11. Mimeault M and Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol. 2010; 224:626-635. [PubMed]
  • 12. Xu J, Kimball TR, Lorenz JN, Brown DA, Bauskin AR, Klevitsky R, Hewett TE, Breit SN, Molkentin JD. GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res. 2006; 98:342-350. [PubMed]
  • 13. Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW, Bauskin AR, Wu L, Pankhurst G, Jiang L, Junankar S, Hunter M, Fairlie WD, Lee NJ, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med. 2007; 13:1333-1340. [PubMed]
  • 14. Chrysovergis K, Wang X, Kosak J, Lee SH, Sik Kim J, Foley JF, Travlos G, Singh S, Joon Baek S, Eling TE. NAG-1/GDF15 prevents obesity by increasing thermogenesis, lipolysis and oxidative metabolism. Int J Obes (Lond). 2014;.
  • 15. Kim JM, Kosak JP, Kim JK, Kissling G, Germolec DR, Zeldin DC, Bradbury JA, Baek SJ, Eling TE. NAG-1/GDF15 transgenic mouse has less white adipose tissue and a reduced inflammatory response. Mediators Inflamm. 2013; 2013-641851..
  • 16. Wang X, Chrysovergis K, Kosak J, Eling TE. Lower NLRP3 inflammasome activity in NAG-1 transgenic mice is linked to a resistance to obesity and increased insulin sensitivity. Obesity (Silver Spring). 2013;.
  • 17. Hampton AL, Hish GA, Aslam MN, Rothman ED, Bergin IL, Patterson KA, Naik M, Paruchuri T, Varani J, Rush HG. Progression of ulcerative dermatitis lesions in C57BL/6Crl mice and the development of a scoring system for dermatitis lesions. J Am Assoc Lab Anim Sci. 2012; 51:586-593. [PubMed]
  • 18. Huang P, Westmoreland SV, Jain RK, Fukumura D. Spontaneous nonthymic tumors in SCID mice. Comp Med. 2011; 61:227-234. [PubMed]
  • 19. VanSaun MN, Lee IK, Washington MK, Matrisian L, Gorden DL. High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am J Pathol. 2009; 175:355-364. [PubMed]
  • 20. List EO, Sackmann-Sala L, Berryman DE, Funk K, Kelder B, Gosney ES, Okada S, Ding J, Cruz-Topete D, Kopchick JJ. Endocrine parameters and phenotypes of the growth hormone receptor gene disrupted (GHR−/−) mouse. Endocr Rev. 2011; 32:356-386. [PubMed]
  • 21. Keipert S, Voigt A, Klaus S. Dietary effects on body composition, glucose metabolism, and longevity are modulated by skeletal muscle mitochondrial uncoupling in mice. Aging Cell. 2011; 10:122-136. [PubMed]
  • 22. Longo VD and Mattson MP. Fasting: Molecular Mechanisms and Clinical Applications. Cell Metab. 2014;.
  • 23. Bishop NA and Guarente L. Genetic links between diet and lifespan: shared mechanisms from yeast to humans. Nat Rev Genet. 2007; 8:835-844. [PubMed]
  • 24. Johnson SC, Rabinovitch PS, Kaeberlein M. mTOR is a key modulator of ageing and age-related disease. Nature. 2013; 493:338-345. [PubMed]
  • 25. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, Pahor M, Javors MA, Fernandez E, et al. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009; 460:392-395. [PubMed]
  • 26. Selman C, Tullet JM, Wieser D, Irvine E, Lingard SJ, Choudhury AI, Claret M, Al-Qassab H, Carmignac D, Ramadani F, Woods A, Robinson IC, Schuster E, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science. 2009; 326:140-144. [PubMed]
  • 27. Li Y, Xu W, McBurney MW, Longo VD. SirT1 inhibition reduces IGF-I/IRS-2/Ras/ERK1/2 signaling and protects neurons. Cell Metab. 2008; 8:38-48. [PubMed]
  • 28. De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 2005; 579:2035-2039. [PubMed]
  • 29. Finch CE and Crimmins EM. Inflammatory exposure and historical changes in human life-spans. Science. 2004; 305:1736-1739. [PubMed]
  • 30. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, Shimomura I, Takayama Y, Herz J, et al. Suppression of aging in mice by the hormone Klotho. Science. 2005; 309:5742 1829-1833. [PubMed]
  • 31. Lorenzini A, Salmon AB, Lerner C, Torres C, Ikeno Y, Motch S, McCarter R, Sell C. Mice producing reduced levels of insulin-like growth factor type 1 display an increase in maximum, but not mean, life span. J Gerontol A Biol Sci Med Sci. 2014; 69:410-419. [PubMed]
  • 32. Wang X, Baek SJ, Eling TE. The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. Biochem Pharmacol. 2013; 85:597-606. [PubMed]
  • 33. Wiklund FE, Bennet AM, Magnusson PK, Eriksson UK, Lindmark F, Wu L, Yaghoutyfam N, Marquis CP, Stattin P, Pedersen NL, Adami HO, Gronberg H, Breit SN, et al. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell. 2010; 9:1057-1064. [PubMed]
  • 34. Baek SJ, Okazaki R, Lee SH, Martinez J, Kim JS, Yamaguchi K, Mishina Y, Martin DW, Shoieb A, McEntee MF, Eling TE. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology. 2006; 131:1553-1560. [PubMed]
  • 35. Csongradi E, Docarmo JM, Dubinion JH, Vera T, Stec DE. Chronic HO-1 induction with cobalt protoporphyrin (CoPP) treatment increases oxygen consumption, activity, heat production and lowers body weight in obese melanocortin-4 receptor-deficient mice. Int J Obes (Lond). 2012; 36:244-253. [PubMed]
  • 36. Auerbach SS, Thomas R, Shah R, Xu H, Vallant MK, Nyska A, Dunnick JK. Comparative phenotypic assessment of cardiac pathology, physiology, and gene expression in C3H/HeJ, C57BL/6J, and B6C3F1/J mice. Toxicol Pathol. 2010; 38:923-942. [PubMed]